Drugs / Astragalus Powder
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03535935 | Jul 2018 → Jun 2022 | diabetic kidney disease | The University of Hong Kong | Unknown | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Astragalus Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03535935 ↗ |
| Known as | huang-qi | “Astragalus, commonly known as huang-qi, is the most prescribed CM or used dietary herb in China for diabetes and DKD.” PMID 33436470 ↗ Jan 2021 |
| Modality | Traditional medicine (herbal / TCM) | “Astragalus, a common herbal medicine and US pharmacopeia-registered food ingredient” PMID 38810556 ↗ Feb 2024 |
| Route | Oral | “add-on oral astragalus granules” PMID 38810556 ↗ Feb 2024 |